
BioCina is an end-to-end CDMO, bringing more than 50 years of pharmaceutical manufacturing heritage to biologic drug substance and sterile drug product manufacturing, from clinical through commercial scale.
Our drug substance expertise spans microbial fermentation, plasmid DNA, and mRNA with LNP encapsulation, based at their Adelaide facility.
Their sterile fill-finish drug product capability, based at the Perth facility, supports biologics and small molecules across blow-fill-seal, vials, pre-filled syringes, cartridges and bottles, with dedicated capabilities for cytotoxic injectables and controlled substances.
For European biotech and pharmaceutical companies, BioCina offers a reliable manufacturing base outside Europe, backed by Australia’s streamlined ethics approvals and fast pathway to first-in-human trials. Facilities are TGA licensed and have passed inspections by the US FDA, EMA, Health Canada, and other regulatory authorities, with a track record supplying more than 140 countries.
Combined with Australia’s R&D tax incentive of up to 43.5% cashback, BioCina supports European programs looking to move quickly from development into clinical and commercial supply.
Contact
Teresa Karnatz

Senior Director of Business Development, EU & UK
Objectives
- Partner with clinical-stage and commercial biotech and pharma companies seeking integrated drug substance and drug product manufacturing across biologics and small molecules
- Engage mRNA, pDNA, and gene therapy developers requiring GMP manufacturing and integrated fill-finish under a single project team
- Connect with oncology, rare disease, and orphan drug companies requiring high-containment cytotoxic fill-finish or flexible small-batch biologics supply
- Support specialty and hospital pharma, generic manufacturers, and controlled substance companies seeking high-volume or specialist sterile fill-finish capabilities
- Engage established pharmaceutical companies looking to derisk their supply chain, access specialist capabilities, or establish a second source
- Build relationships with CMC consultants, regulatory advisors, and outsourcing professionals who recommend manufacturing partners to their clients
News
Expanded Integrated Capabilities
Combines BioCina’s expertise in microbial, pDNA, mRNA, and LNP drug substance manufacturing with NovaCina’s advanced sterile fill-finish solutions for biologics and small molecules, delivering seamless end-to-end development and manufacturing
Regulatory Excellence
State-of-the-art facilities in Adelaide and Perth, fully licensed and inspected by US FDA, EMA, TGA, Health Canada, and other leading global authorities, ensuring world-class compliance and quality